What the Court Record Does Not Count

Imagine you are in kidney failure. Your kidneys have stopped cleaning your blood, so three times a week you sit in a dialysis chair for four hours while a machine does the job your organs no longer can. The people around you in that room are doing the same. Some of them have been coming for years. The nurses know their names. It is a brutal, exhausting routine that keeps you alive.

You trust the machine. You trust the fluid running through the machine. You trust the company that makes the fluid because you have no real choice. You are not a pharmacist. You are not an engineer. You are a sick person trying to survive, and the entire system, your doctor, your dialysis center, your insurance payer, is built on the assumption that the products being used on your body are safe.

Then your heart stops.

For the families who lost someone in a Fresenius dialysis chair, the years that followed were not just grief. They were a legal labyrinth. Wrongful death claims. Product liability suits. A massive multidistrict litigation proceeding that consolidated thousands of cases into a single federal court in Massachusetts. A global settlement that resolved the “vast majority” of individual claims but did not name a single number publicly in this court record. Families who opted into that settlement traded their right to fight for whatever Fresenius offered. Families who did not opt in were severed from the proceeding.

The Medicare and Medicaid payers who filed the 2018 lawsuit were not the patients themselves. They were the entities that paid the medical bills when those patients ended up in emergency rooms after their hearts failed during or after dialysis. That money came from public insurance programs, programs funded by working people’s taxes and premiums. When Fresenius’s product hurt someone, the public absorbed the cost. When those payers tried to get that money back six years later, a federal appeals court told them: too late.

No document in this case names a single patient. No document here describes what a dialysis-related cardiopulmonary arrest looks and feels like for the person experiencing it, or for the family member who gets the phone call. The entire legal architecture, the tolling rules, the class action machinery, the statute of limitations clock, exists at a level of abstraction so far removed from those moments that the human beings at the center of this case have become invisible inside their own litigation.

That is not a flaw in how the court wrote its opinion. That is a feature of how corporate liability law is designed to function. By the time any of this reached a judge, the question was not “Did Fresenius hurt people?” The question was “Did the lawyers file the right paperwork on the right calendar date?” The people died either way.

They Said the Quiet Part Out Loud. It’s In the Court Record.

These are direct quotes from the U.S. Court of Appeals First Circuit opinion, No. 23-1820, decided March 17, 2025. No paraphrase. No invention.

“On March 29, 2012, Fresenius issued a public memorandum explaining that GranuFlo could lead to cardiopulmonary arrest in certain patients and advising doctors to ‘exercise their best clinical judgment’ when prescribing and administering treatments.”

“In January of 2015, the court stated that the 2014 adoption of the Master Complaint and the filing of the Short Form Complaint did not ‘necessarily supersede[]’ a plaintiff’s original complaint ‘for purposes of motion to dismiss practice.'”

“Leadership counsel was nevertheless ‘not planning on moving for certification,’ and that ‘these cases were filed, for the most part, with respect to the issue of equitable tolling for the purposes of the limitations period, and for now our preference is to just leave them as they are.'”

“To allow such a gambit to substitute for pleading and actively pursuing a class action would run contrary to the aims of American Pipe, the ‘watchwords’ of which are ‘efficiency and economy of litigation.'”

A Decade of Delay: How the Clock Was Managed

From Fresenius’s own internal memo to the final appellate ruling, every critical event in this case is separated by years of procedural stalling. The timeline below shows how long wrongdoing continued before any accountability was attempted, and how the statute of limitations ultimately swallowed the case.

What Fresenius Said. What the Record Shows.

The Damage That Outlasts Every Dismissal

Public Health

GranuFlo was used in hemodialysis centers across the United States, administered to some of the most physically vulnerable people in the country: patients in end-stage renal disease who depend on dialysis to survive. The documented risk, cardiopulmonary arrest, is among the most severe acute medical events a human body can undergo.

• Fresenius’s own March 2012 memorandum confirmed the link between GranuFlo and cardiopulmonary arrest. This was not a theoretical risk identified by regulators after the fact; the manufacturer documented it internally first.
• The 2012 disclosure triggered a “stream of wrongful death and personal injury lawsuits,” according to the First Circuit opinion. The plural “stream” indicates this was a systemic problem affecting multiple patients, not an isolated incident.
• GranuFlo and its companion product NaturaLyte were allegedly in use from at least May 2003, per the Berzas class action complaint’s proposed class definition. If the cardiac risk existed throughout that period, patients may have been exposed for nearly a decade before any public warning was issued.
• Dialysis patients have no practical alternative to continuing dialysis. They could not avoid exposure by stopping use of the product. The cardiac risk was embedded in the treatment they required to stay alive.
• The litigation was consolidated as multidistrict litigation (MDL), a procedural mechanism reserved for cases involving a common set of facts across a large number of plaintiffs. MDL status signals a problem of national scale, not an individual product defect.

Economic Inequality

The financial aftermath of the GranuFlo scandal did not fall on Fresenius. It was absorbed by public insurance programs, individual patients’ families, and the taxpaying public, while Fresenius’s corporate structure allowed it to negotiate a private global settlement on its own terms.

• MSP Recovery’s 2018 lawsuit was filed specifically because Medicare and Medicaid payers, public programs, had already paid for the emergency and ongoing medical care of GranuFlo patients. The harm to the public treasury was real and documented before the lawsuit was even filed.
• The global settlement Fresenius negotiated in 2016 was described in the court record only as resolving the “vast majority” of individual claims. The settlement amount, the per-patient payout, and the terms are not disclosed in this court record. Patients and their families were offered an opaque deal with no public accountability attached to it.
• Families who did not opt into the settlement were “severed” from the MDL proceeding. Severance means they lost the collective procedural weight of thousands of plaintiffs and had to pursue claims alone, a resource and legal disadvantage that overwhelmingly affects lower-income families without independent legal counsel.
• MSP’s claims were brought under the laws of Massachusetts, New York, and Connecticut. The assignors of those claims were insurance entities that had already absorbed costs on behalf of patients. When those entities were time-barred from recovery, the cost of Fresenius’s negligence remained with the public systems that had already paid it.
• Fresenius USA Sales, one of the named corporate entities, had dissolved in 2010, two years before the 2012 memo and years before any lawsuits. A dissolved entity cannot pay a judgment. This is precisely how corporate subsidiaries function as financial firewalls: the entity closest to sales activity ceases to exist before accountability arrives.

Putting a Number on What Accountability Costs

The court record does not disclose the Fresenius global settlement total. What the record does disclose is that MSP Recovery was attempting to recoup costs paid by Medicare and Medicaid payers. The statutes of limitations at issue were either three or four years. The following metric reflects the structural consequence of the dismissal.

Where to Apply Pressure and Who to Watch

The First Circuit’s ruling does not mean Fresenius is innocent or that GranuFlo did not harm people. It means one set of plaintiffs filed too late, and that their lawyers used a legal placeholder strategy that courts will not protect. The underlying conduct, a company knowing its product could stop a patient’s heart and issuing a memo instead of a recall, remains on the record.

Corporate Leadership to Monitor

• The current executive leadership of Fresenius Medical Care Holdings, Inc. controls corporate strategy and settlement policy. [REDACTED – Not in Source: specific executive names]
• The board of directors of Fresenius Medical Care Holdings, Inc. sets governance policy and approved or ratified the global settlement structure. [REDACTED – Not in Source: specific board member names]
• The legal teams at Dowd Bennett LLP and Hogan Lovells US LLP represented Fresenius in this appeal. Their client list and future engagements are matters of public record worth tracking.

Regulatory Watchlist

• FDA (Food and Drug Administration): GranuFlo is a medical device-adjacent dialysis product. The FDA’s Center for Devices and Radiological Health (CDRH) is the relevant division. File a MedWatch adverse event report if you or someone you know was harmed by GranuFlo or NaturaLyte.
• CMS (Centers for Medicare and Medicaid Services): CMS oversees dialysis facility certification and reimbursement. Complaints about dialysis center practices can be filed directly with CMS or through your State Survey Agency.
• DOJ Civil Division: The Department of Justice has authority to bring False Claims Act cases when Medicare or Medicaid funds are implicated in fraud or negligence. Public whistleblowers (qui tam relators) can trigger DOJ investigations independently of private civil suits.
• FTC (Federal Trade Commission): If Fresenius’s marketing of GranuFlo or NaturaLyte involved deceptive trade practices, the FTC has independent jurisdiction to investigate and sanction.
• State Attorneys General: Massachusetts, New York, and Connecticut are the three states whose laws governed MSP’s claims. Each of those states’ AGs has consumer protection authority that is not subject to the same federal statute of limitations constraints.

Grassroots and Mutual Aid Recommendations

• If you or a family member is a dialysis patient, request in writing from your dialysis center the complete list of acid concentrates and dialysate products currently in use. You have a right to that information. Document every product name and manufacturer before you need it.
• Connect with the American Association of Kidney Patients (AAKP) and the Dialysis Patient Citizens (DPC) advocacy organizations. Both track legislative and regulatory developments in dialysis care and have lobbying capacity that individual patients do not.
• Share this investigation with anyone you know on dialysis or in the dialysis care workforce. Nurses, technicians, and social workers inside dialysis centers are often the first to notice patterns of patient harm and can file anonymous complaints with CMS or the FDA without employer retaliation protections being waived.
• Statute of limitations problems are a systemic class action design flaw, not an individual failure. Contact your Congressional representative and ask them to support legislation extending statutes of limitations in cases where a manufacturer knowingly delayed disclosure of a product defect. The timeline in this case shows that Fresenius’s 2012 memo was the starting gun. Congress can change when that clock starts.
• If you believe you may have a claim related to GranuFlo or NaturaLyte and have not yet consulted a lawyer, do it today. Every day of delay is a day off your statute of limitations clock.